Viridian Therapeutics, Inc. (VRDN) Report Analysis
Corporate Events
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2000 Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2000 Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2000 Growth Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2000 Growth Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2000 Value Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2000 Value Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell Small Cap Comp Growth Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell Small Cap Comp Growth Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 3000 Growth Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 3000 Growth Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 3000 Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 3000 Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 3000 Value Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 3000 Value Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell Small Cap Completeness Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell Small Cap Completeness Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell Small Cap Comp Value Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell Small Cap Comp Value Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2500 Value Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2500 Value Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2500 Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2500 Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2000 Dynamic Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2000 Dynamic Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 3000E Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 3000E Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 3000E Value Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 3000E Value Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 3000E Growth Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 3000E Growth Index
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2500 Growth Index
2022-06-24 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to Russell 2500 Growth Index
Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer
2022-06-23 11:00:00
Viridian Therapeutics, Inc. appointed of Carrie Melvin as Chief Operating Officer Ms. Melvin has over 20 years of experience at pharmaceutical and biotechnology companies. She has held roles of increasing responsibility in development and commercial stage companies, including leadership responsibilities for worldwide clinical development operations in oncology and rare diseases. She also has extensive experience leading data management, clinical program management, site management, medical writing, vendor management, and supply chain activities. Prior to joining Viridian, Ms. Melvin served as Senior Vice President of Clinical Development Operations at X4 Pharmaceuticals, Inc. during which time she led the clinical development operations function. Prior to joining X4 Pharmaceuticals, she served as Vice President of Global Clinical Sciences and Delivery, Oncology at GSK, plc a role she took on after GSK acquired TESARO, Inc. in January 2019. Prior to the acquisition, she served as Vice President of Clinical Operations at TESARO. During her time at GSK and TESARO, she oversaw clinical development operations for the oncology portfolio, including developing operational strategy and vendor partnerships. Prior to TESARO, Ms. Melvin served as the Vice President, and Head of Global Clinical Operations at Kura Oncology, Inc. where she established and led the clinical operations group. Ms. Melvin received her MBA from the Boston University Questrom School of Business and her BSN degree with higher distinction from the University of Rhode Island.
Viridian Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 11:30 AM
2022-06-04 12:15:00
Viridian Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 11:30 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Jonathan Violin, Co-Founder, CEO, President & Director.
Viridian Therapeutics, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 03:30 PM
2022-05-28 04:54:00
Viridian Therapeutics, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 03:30 PM. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States. Speakers: Jonathan Violin, Co-Founder, CEO, President & Director.
Viridian Therapeutics, Inc., Q1 2022 Earnings Call, May 12, 2022
2022-05-03 12:00:00
Viridian Therapeutics, Inc., Q1 2022 Earnings Call, May 12, 2022
Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022
2022-05-03 12:00:00
Viridian Therapeutics, Inc. announced that they will report Q1, 2022 results After-Market on May 12, 2022
Viridian Therapeutics, Inc. - Shareholder/Analyst Call
2022-04-27 21:13:00
AGM
Viridian Therapeutics, Inc., Annual General Meeting, Jun 08, 2022
2022-04-27 21:13:00
Viridian Therapeutics, Inc., Annual General Meeting, Jun 08, 2022, at 09:00 US Eastern Standard Time. Agenda: To consider and elect the Class I director nominee named in the Proxy Statement to serve until the 2025 Annual Meeting of Stockholders or until his successor is duly elected and qualified; to consider and ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022; to consider and approve, on an advisory basis, the compensation of named executive officers; and to consider the transact any other matters that may properly come before the Annual Meeting or any adjournments or postponements thereof.
Viridian Therapeutics, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-14-2022 04:30 PM
2022-04-06 12:00:00
Viridian Therapeutics, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-14-2022 04:30 PM. Speakers: Jonathan Violin, CEO, President & Director.
Viridian Therapeutics, Inc. Secures Flexible Credit Facility for Up to $75 Million from Hercules Capital
2022-04-04 20:05:00
Viridian Therapeutics, Inc. has entered into a debt financing agreement with Hercules Capital, Inc. for up to $75 million. Under the terms of the agreement, Viridian drew an initial $5 million at closing. An additional $20 million is available at the company’s request through June 15, 2023, with an additional $25 million available upon the Company’s achievement of certain milestones, and the remaining $25 million available subject to final lender approval. The Company is under no obligation to draw funds in the future. The facility carries a single-digit cost of capital.
Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.
2022-04-04 00:00:00
Viridian Therapeutics, Inc. announced that it has entered into a debt financing agreement to receive $75,000,000 in a round of funding on April 4, 2022. The transaction will include participation from new lender Hercules Capital, Inc. The transaction will be completed in multiple tranches. On the same date, the company has received $5,000,000 in its first tranche. The company will receive $20,000,000 at its request by June 15, 2023 and it will receive another $25,000,000 upon its achievement of certain milestones, and the remaining $25,000,000 will be received subject to final lender approval. The Company is under no obligation to draw funds in the future. The facility carries a single-digit cost of capital.
JMP Securities LLC, the JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022
2022-02-16 16:45:00
JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022
2022-02-14 21:00:00
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.
Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022
2022-02-11 23:04:00
Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002
2022-01-31 12:00:00
Viridian Therapeutics, Inc. announced the United States Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application of VRDN-002. The Company’s next generation IGF-1R antibody, VRDN-002, is a humanized monoclonal antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low-volume, subcutaneous (SC) injection for the treatment of thyroid eye disease (TED). The IND application clearance allows the Company to proceed with its planned first-in-human Phase 1 clinical trial of VRDN-002, which is a single ascending dose study to explore safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered VRDN-002 in healthy volunteers. Data from this Phase 1 trial are expected to be announced in mid-2022 and will inform the feasibility of a low-volume and/or low-frequency SC dosing paradigm for TED patients. This IND acceptance is the first of multiple regulatory, clinical, and operational milestones expected in 2022, including top-line data from VRDN-001 Phase 1/2 proof of concept trial in the second quarter of 2022, and top-line data from VRDN-002 Phase 1 trial in mid-2022.
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration
2022-01-04 12:00:00
Viridian Therapeutics, Inc. announced the submission of an investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for VRDN-002, a humanized monoclonal antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low-volume, subcutaneous injection for the treatment of thyroid eye disease (TED). Viridian submitted the IND for VRDN-002 in December 2021. The company is seeking authorization to initiate a Phase 1 single ascending dose clinical trial to explore safety, tolerability, pharmacokinetics, and target engagement of intravenous VRDN-002 in healthy volunteers. Data from this Phase1 trial aims to test the feasibility of a low-volume and/or low-frequency dosing paradigm and are expected to be announced in mid-2022.
Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
2021-12-20 12:00:00
Viridian Therapeutics, Inc. announced the first subject was dosed in a Phase 1/2 proof-of-concept clinical trial for VRDN-001, a monoclonal antibody that blocks the IGF-1 receptor with sub-nanomolar potency. IGF-1R blockade is a clinically validated mechanism of action for the treatment of TED. The Phase 1/2 trial is designed to evaluate safety, tolerability, pharmacokinetics, and potential efficacy of VRDN-001. The trial includes both healthy volunteers and randomized, placebo-controlled cohorts of TED patients and will assess multiple measures of the signs and symptoms of TED, including proptosis – the bulging of eyes characteristic of TED. The Company expects to announce top line data from the proof-of-concept portion of the trial in the second quarter of 2022. The trial protocol allows for additional TED patient cohorts to assess differing treatment paradigms that may offer advantages over currently available therapies and may reduce the burden of patient treatment. The clinical development plan for VRDN-001 was informed by safety, tolerability, pharmacokinetic, and pharmacodynamic data from more than 100 oncology patients who were previously administered this antibody under the name AVE1642.
Viridian Therapeutics, Inc. Presents at LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan-05-2022
2021-12-16 17:17:00
Viridian Therapeutics, Inc. Presents at LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan-05-2022 .
LifeSci Partners, LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan 05, 2022 through Jan 07, 2022
2021-11-20 00:00:00
LifeSci Partners, LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan 05, 2022 through Jan 07, 2022.
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application for VRDN-001, IGF-1R Antibody for Treatment of Thyroid Eye Disease
2021-11-15 12:00:00
Viridian Therapeutics, Inc. announced the U.S. Food and Drug Administration clearance of its Investigational New Drug application for VRDN-001, which the company is developing for the treatment of thyroid eye disease (TED). VRDN-001 is a monoclonal antibody that binds and blocks the IGF-1R signaling pathway with sub-nanomolar affinity. This mechanism of action is clinically and commercially validated for the treatment of TED. The company’s first clinical trial for VRDN-001 is a Phase 1/2 proof of concept trial including multiple randomized, placebo-controlled cohorts of TED patients to assess the potential for VRDN-001 to provide rapid improvement of signs and symptoms of TED, including proptosis. The protocol for this trial allows for additional patient cohorts to assess differing treatment paradigms that may offer advantages over currently available therapies and mitigate patient treatment burden. The company expects to announce top line data from the proof of concept portion of the trial in the second quarter of 2022.
Viridian Therapeutics, Inc. has filed a Shelf Registration in the amount of $350 million.
2021-11-08 00:00:00
Viridian Therapeutics, Inc. has filed a Shelf Registration in the amount of $350 million. Security Name: Common Stock Security Name: Preferred Stock Security Name: Debt Securities Security Name: Warrants Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration
Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.
2021-11-08 00:00:00
Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
Viridian Therapeutics, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM
2021-11-03 21:30:00
Viridian Therapeutics, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom. Speakers: Jonathan Violin, CEO, President & Director.
Viridian Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 10:55 AM
2021-11-03 21:30:00
Viridian Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 10:55 AM. Speakers: Jonathan Violin, CEO, President & Director.
Viridian Therapeutics, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021 08:50 AM
2021-10-15 01:02:00
Viridian Therapeutics, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021 08:50 AM. Venue: Rancho Palos Verdes, California, United States. Speakers: Jonathan Violin, CEO, President & Director, Kristian Humer, CFO, Chief Business Officer, Principal Financial Officer & Principal Accounting Officer.
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001
2021-10-14 12:00:00
Viridian Therapeutics, Inc. announced the submission of an investigational new drug (IND) application to the United States Food and Drug Administration (FDA). The Company is seeking authorization to initiate a Phase 1/2 clinical trial of VRDN-001, an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody in development for the treatment of thyroid eye disease (TED), a debilitating disease that can cause proptosis (bulging eyes), double vision, and potential blindness. The company believes this clinical trial could provide key proof of concept clinical data in TED patients, with the potential to show clinically meaningful improvements in signs and symptoms of TED, including proptosis. The company expects to announce top line clinical data from the proof of concept portion of the proposed trial in the second quarter of 2022.
Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999909 million.
2021-09-21 00:00:00
Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999909 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,185,454 Price\Range: $11 Discount Per Security: $0.66 Security Name: Series B Preferred Stock Security Type: Preferred Stock Securities Offered: 23,126 Price\Range: $733.37 Discount Per Security: $44.0022 Security Features: Convertible
Certain Common Stock of Viridian Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2021.
2021-09-21 00:00:00
Certain Common Stock of Viridian Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2021. These Common Stock will be under lockup for 91 days starting from 21-SEP-2021 to 21-DEC-2021. Details: The company's executive officers and directors and certain of stockholders have agreed that they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of any shares of our common stock beneficially owned (as such term is used in Rule 13d-3 of the Exchange Act) or any other securities so owned that are convertible into or exercisable or exchangeable for common stock for a period of 90 days after the date of the prospectus.
Certain Stock Options of Viridian Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2021.
2021-09-21 00:00:00
Certain Stock Options of Viridian Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2021. These Stock Options will be under lockup for 91 days starting from 21-SEP-2021 to 21-DEC-2021. Details: The company's executive officers and directors and certain of stockholders have agreed that they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of any shares of our common stock beneficially owned (as such term is used in Rule 13d-3 of the Exchange Act) or any other securities so owned that are convertible into or exercisable or exchangeable for common stock for a period of 90 days after the date of the prospectus.
Certain Warrants of Viridian Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2021.
2021-09-21 00:00:00
Certain Warrants of Viridian Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2021. These Warrants will be under lockup for 91 days starting from 21-SEP-2021 to 21-DEC-2021. Details: The company's executive officers and directors and certain of stockholders have agreed that they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of any shares of our common stock beneficially owned (as such term is used in Rule 13d-3 of the Exchange Act) or any other securities so owned that are convertible into or exercisable or exchangeable for common stock for a period of 90 days after the date of the prospectus.
Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.
2021-09-20 00:00:00
Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Security Name: Series B Preferred Stock Security Type: Preferred Stock Security Features: Convertible
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to S&P Global BMI Index
2021-09-20 00:00:00
Viridian Therapeutics, Inc.(NasdaqCM:VRDN) added to S&P Global BMI Index
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021
2021-08-24 20:29:00
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.
Viridian Therapeutics, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 01:45 PM
2021-08-05 12:30:00
Viridian Therapeutics, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 01:45 PM. Speakers: Barrett Katz, Chief Medical Officer, Jonathan Violin, CEO, President & Director.
Viridian Therapeutics, Inc. Appoints Kristian Humer as Chief Financial Officer
2021-07-26 11:36:00
On July 26, 2021, Viridian Therapeutics, Inc. announced the appointment of Kristian Humer as the company’s Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Humer will also serve as the company’s Principal Financial Officer and Principal Accounting Officer. Mr. Humer, most recently served as Managing Director of Banking, Capital Markets and Advisory for the Global Healthcare team at Citigroup Inc., from January 2017 to July 2021, where he helped lead the firm’s investment banking advisory engagements for small- and mid-sized biopharma and select large cap pharmaceutical companies.
Viridian Therapeutics, Inc. Announces the Appointment of Kristian Humer as Chief Business Officer
2021-07-26 11:36:00
Viridian Therapeutics, Inc. announced the appointment of Kristian Humer as the Company’s Chief Business Officer, effective immediately. Mr. Humer will also serve as the Company’s Principal Financial Officer and Principal Accounting Officer. Mr. Humer, most recently served as Managing Director of Banking, Capital Markets and Advisory for the Global Healthcare team at Citigroup Inc., from January 2017 to July 2021, where he helped lead the firm’s investment banking advisory engagements for small- and mid-sized biopharma and select large cap pharmaceutical companies.
Viridian Therapeutics, Inc. Appoints Jennifer K. Moses as A Member of the Board
2021-07-15 20:13:00
On July 14, 2021, the board of directors of Viridian Therapeutics, Inc. appointed Jennifer K. Moses as a member of the Board. Ms. Moses will serve as a Class II director until the company's 2023 Annual Meeting of Stockholders or until her successor is duly elected and qualified, effective immediately. Ms. Moses was also appointed as Chair of the Audit Committee of the Board. Ms. Moses has served as the Chief Financial Officer of G1 Therapeutics, Inc. since May 2019. Viridian has successfully assembled an accomplished management team and raised significant capital over the past few quarters to advance the development of multiple product candidates designed to create meaningful new options for patients suffering from Thyroid Eye Disease.
Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021
2021-06-29 20:28:00
Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.
Fundamental Summary
At a high level, the metrics from Viridian Therapeutics's Q4 financial report release were demonstrably negative. Specifically, their growth, value, and income factors indicate an execution challenge when it comes to generating exciting and consistent growth. These results indicate a weak growth potential for Viridian Therapeutics's stock's price moving forward. Correspondingly, Viridian Therapeutics received a ranking of 56 and a UNDERPERFORM recommendation.
Viridian Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 0.216 million compared to USD 1.45 million a year ago. Net loss was USD 25.69 million compared to USD 18.46 million a year ago. Basic loss per share from continuing operations was USD 0.98 compared to USD 2.91 a year ago.
Business Description
Viridian Therapeutics, a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics in January 2021. Viridian Therapeutics was founded in 2006 and is headquartered in Waltham, Massachusetts.
Sector Overview
Viridian Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Viridian Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -51.6 | 58.8% | 63 | |
| Net Cashflow | -3.6 | -103.3% | 72 | |
| Capital Expenditure | -0.3 | -55.1% | 43 | |
| Asset Turnover | 0.0 | -19.8% | 45 | |
| Free Cashflow | -4.6 | 29.0% | 87 |
* All values are TTM
The below chart reflects Viridian Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Viridian Therapeutics's peer average final assessment score stands on 61.0, Viridian Therapeutics's score is 56.
- VRDN
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Viridian Therapeutics's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Viridian Therapeutics's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 42.
5D MA
10.94
50D MA
12.5
200D MA
16.94
MACD
-0.6
RSI
17.96
STOCH
4.74
Balance Sheet Analysis
Overall, Viridian Therapeutics's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. Viridian Therapeutics publishes impressive results related to book value factors in this report. Specifically, price to book ratio (P/B) now sits at 8.8 and represents a 18.8% change from the previous report. These book value factor numbers show that management has been prudent in focusing on efficient growth. We believe the stock price has room to grow to reflect its intrinsic value accurately. The company's book value factors component, therefore, received a grade of 76. Also, The company's assets section could set high expectations for Viridian Therapeutics's future attractiveness, as they went to 203.7, which is a -7.9% change from the last period. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Therefore, its asset component earned a score of 72. That said, one metric, Cash & Equivalents, stood out as strongly negative. Viridian Therapeutics did a poor job related to managing cash and cash equivalents this period, which stood at 42.3, representing a -69.5% change from the previous filing. Their anemic growth in cash and cash equivalents, specifically in contrast to their industry peers' performance, should hurt their stock price. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their cash and cash equivalents with a score of 37. Therefore, the company's balance sheet earned a grade of 65.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 203.7 | -7.9% | 72 |
| Liabilities | 16.0 | -3.7% | 56 |
| Price to Book | 8.8 | 18.8% | 76 |
| Cash & Equivalents | 42.3 | -69.5% | 37 |
| Equity | 53.9 | 24.9% | 44 |
The below chart describes Viridian Therapeutics's performance as reflected on its balance sheet with respect to its peers. While Viridian Therapeutics received a balance sheet score of 65, the average of its peers stands on 63.0.
- VRDN
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 2 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 5 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 6 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 7 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 8 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 9 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 10 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 11 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 12 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 13 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 14 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 15 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 16 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 20 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 21 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 22 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 24 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 33 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 35 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 37 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 41 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 43 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 45 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 51 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 59 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 63 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 65 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 74 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 79 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 87 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 88 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
A deep look into Viridian Therapeutics's income statement metrics showed some disappointing metrics. The most troubling factors we're looking at are the EBITDA and Revenue Efficiency . Viridian Therapeutics's EBIDTA now sits at -79.5 and represents -12.2% change from the last reporting period. This parameter coud affect companies in the same industry and market capitalization by up to 23.8%. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Its EBITDA movement, therefore, received a grade of 50. Also, Viridian Therapeutics management did an underwhelming job managing revenue efficiency this past period. Viridian Therapeutics's revenue efficiency is 3.0 according to the metrics in the current filing, which represents a 5.7% change from the previous report. This metric might have a 12.9 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency, specifically in contrast to their industry peers', isn't encouraging. As a result, their revenue efficiency earned a score of 55. However, we can draw some encouragement from Viridian Therapeutics's momentum in cash_flow generation. Viridian Therapeutics's reported return on equity (ROE) ratio was -51.6, representing a change of 58.8%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 63. Therefore, its income statement earned a grade of 53.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -79.5 | -12.2% | 50 |
| Total Revenues | 3.0 | 5.7% | 55 |
| Return on Equity | -51.6 | 58.8% | 63 |
The below chart describes Viridian Therapeutics's performance as reflected on its income statement with respect to its peers. While Viridian Therapeutics received a income statement score of 53 , the average of its peers stands on 65.0.
- VRDN
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 2 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 5 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 6 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 7 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 8 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 9 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 10 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 11 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 12 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 13 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 14 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 15 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 16 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 20 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 21 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 22 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 24 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 33 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 35 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 37 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 41 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 43 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 45 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 51 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 59 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 63 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 65 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 74 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 79 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 87 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 88 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Free Cash flow and Net Cash Flow stand out as the most significant drivers of Viridian Therapeutics's cash flow's strength. Free cash flow numbers published by Viridian Therapeutics were -4.6, which was a 29.0% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.8%. These free cash flow numbers show that management has executed well while generating cash flow and encouraging growth. The company's free cash flow movement, therefore, received a grade of 87. Also, Viridian Therapeutics presents exciting net cash flow numbers for its recent financial release, illustrated by a net cash flow of -3.6, which is a change of -103.3% from the last filing. The company is headed in the right direction regarding business priorities, exhibiting prudent net cash flow management and growth. Hence, its net cash flow earned a score of 72. On the other hand, Capital Expenditure, jumped out as looking rather underwhelming. Viridian Therapeutics's management was ineffective in materially improving CapEx, which now sits at -0.3 and represents a -55.1% change from the previous report. This performance is all the more uninspiring relative to their peers and competitors. Therefore, their CapEx movement component earned a score of 43. Because the company's management is doing an excellent job managing these critical metrics, the cash flow was given a score of 65.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -3.6 | -103.3% | 72 |
| Capital Expenditure | -0.3 | -55.1% | 43 |
| Asset Turnover | 0.0 | -19.8% | 45 |
| Free Cashflow | -4.6 | 29.0% | 87 |
The below chart describes Viridian Therapeutics's performance as reflected on its cash flow with respect to its peers. While Viridian Therapeutics received a cash flow score of 65, the average of its peers stands on 70.0.
- VRDN
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 2 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 5 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 6 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 7 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 8 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 9 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 10 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 11 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 12 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 13 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 14 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 15 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 16 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 20 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 21 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 22 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 24 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 33 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 35 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 37 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 41 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 43 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 45 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 51 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 59 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 63 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 65 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 74 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 79 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 87 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 88 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.